U-Neuron BiomedicalROCO:6973 12 Quick Ratio is 16.20 as of Dec. 2025, which is 12% above its 10-year median of 14.50. GuruFocus rates ROCO:6973 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, U-Neuron Biomedical ranks better than 88.59% on this metric.
U-Neuron Biomedical has a quick ratio of 16.20. It generally indicates good short-term financial strength.
The historical rank and industry rank for U-Neuron Biomedical's Quick Ratio or its related term are showing as below:
ROCO:6973'
s Quick Ratio Range Over the Past 10 Years
Min: 7.38 Med: 14.5 Max: 22.12
Current: 16.2
During the past 6 years, U-Neuron Biomedical's highest Quick Ratio was 22.12. The lowest was 7.38. And the median was 14.50.
ROCO:6973's Quick Ratio is ranked better than 88.59% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs ROCO:6973: 16.20
U-Neuron Biomedical (ROCO:6973) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
U-Neuron Biomedical Quick Ratio Related Terms
U-Neuron Biomedical Quick Ratio Historical Data
* Premium members only.
The historical data trend for U-Neuron Biomedical's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6973 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, U-Neuron Biomedical's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
U-Neuron Biomedical Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Quick Ratio distribution charts can be found below:
* The bar in red indicates where U-Neuron Biomedical's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
U-Neuron Biomedical's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
U-Neuron Biomedical (ROCO:6973) has a Quick Ratio of 16.20 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on U-Neuron Biomedical and its competitors. This is 12% above median its historical median of 14.50. Over the past decade, U-Neuron Biomedical's Quick Ratio has ranged from 7.38 to 22.12. According to the industry distribution chart, U-Neuron Biomedical ranks #161 out of 1411 companies in the Biotechnology industry, placing it in the top 11.4%.
Is U-Neuron Biomedical's Quick Ratio too high?
U-Neuron Biomedical's current Quick Ratio of 16.20 is 12% above median its 10-year median of 14.50. Over the past 10 years, this metric has ranged from a low of 7.38 to a high of 22.12. The Biotechnology industry median Quick Ratio is 3.59. U-Neuron Biomedical's value of 16.20 is 351.3% above this industry median. Based on the distribution chart, U-Neuron Biomedical ranks #161 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, U-Neuron Biomedical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, U-Neuron Biomedical ranks #161 out of 1411 companies for Quick Ratio. This places U-Neuron Biomedical in the top 11% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. U-Neuron Biomedical's value of 16.20 is 351.3% above this benchmark. Historically, U-Neuron Biomedical's own Quick Ratio has ranged from 7.38 to 22.12 over the past decade. While the company's 10-year median is 14.50 vs. the industry median of 3.59, U-Neuron Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. U-Neuron Biomedical's current Quick Ratio of 16.20 is 351.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on U-Neuron Biomedical and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. U-Neuron Biomedical's current Quick Ratio is 16.20, which is 12% above median its own 10-year median of 14.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
U-Neuron Biomedical (ROCO:6973) has a current Quick Ratio of 16.20. The current Quick Ratio is 16.20, which is 12% above median its 10-year median of 14.50 and 351.3% above the Biotechnology industry median of 3.59. U-Neuron Biomedical's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current Quick Ratio is 16.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
12GF Score
Get the complete analysis for ROCO:6973
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6973 has been successfully added to your 
